Title : A novel multiplex serology assay to evaluate immune response to RSV, SARS CoV-2 and influenza
Abstract:
Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and influenza are prominent respiratory pathogens that significantly impact global public health. Each of these viruses poses distinct challenges and complexities, contributing to respiratory infections that range from mild illnesses to severe, life-threatening conditions. Understanding the immune responses elicited by RSV, SARS-CoV-2, and influenza is crucial for effective disease management, preventive strategies, and the development of targeted interventions. Often called a “tripledemic” due to their seasonal coincidence, there are now vaccines for all three to prevent severe disease and limit transmission. In light of the emergence of novel SARS-CoV-2 variants, the need for surveillance data on new RSV vaccines, and the unpredictability of the influenza virus caused by circulating strains that vary from year to year, the imperative for a reliable and sensitive tool to concurrently monitor all three infections has become increasingly evident.
In this study, we present an innovative tool designed for monitoring serological responses to RSV, SARS-CoV-2, and influenza. This multiplex serological assay offers quantitative measurements of antibodies targeting diverse strains of influenza, different variants of SARS-CoV-2, and the common virus/vaccine component associated with RSV. The development and validation of such a comprehensive tool are essential steps toward enhancing our capacity to assess and manage the evolving landscape of these respiratory infections. Intra- and inter-plate precision and accuracy, calibrator performance, and control measurements were assessed as part of the validation of these assays. Quantitation spans multiple logs of dynamic range, reducing the need to test multiple sample dilutions. This tool holds promise for enhancing our understanding, assessment, and management of the dynamic serological landscape presented by RSV, SARS-CoV-2, and influenza infections and vaccinations.
Audience Take Away Notes
- A multiplex method for testing and monitoring serological responses to RSV, SARS-CoV-2, and influenza
- They can use the V-PLEX Respiratory Panel 4 (IgG) Kit for at-risk populations to distinguish between vaccinated and/or infected individuals versus negative individuals, for surveillance, in high throughput, and simultaneously measure IgG levels to multiple respiratory antigens supporting exploratory R&D to design treatments, assess mechanism of action, for correlate of protection work
- The MSD multiplex sample testing platforms cover a wide range of biomarkers
- It rather than perform singleplex assays, this allows measurement of 9 Respiratory antigens in 1 well, saving on sample volume, giving more consistent measurement, saving time, money and volume for method development
- It will ensure there is no variability in the measurement due to differences due to variables relating to using 9 singleplex assays- which requires higher sample volume, a variety of pipetting days, freeze/thaw cycles and methods. Nine respiratory antigens are assessed for functional IgG concentration simultaneously
- The V-PLEX Respiratory Panel 4 is a validated, quantitative, multiplexed RUO serology kit that accurately and precisely quantifies IgG antibodies against proteins: CoV-2 Spike (wild-type), CoV-2 Nucleocapsid Spike (XBB.1.5), Flu A/Wisconsin/588/2019 (H1N1), Flu A/H7/Shanghai/2013, Flu A/Darwin/6/2021 HA (H3N2), Flu B/Austria/1359417/2021 (B/Victoria-like), Flu B/Phuket/3073/2013 (B/Yamagata-like) and RSV pre-fusion F
